Study for adults with PSC cirrhosis

IRB/UVA Tracking #
Principal Investigator
Stephen H Caldwell
Jennifer Greene
Contact Email
Contact Phone
Official Trial Title
A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects with Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
Study Description

The Division of Gastroenterology and Hepatology seeks adults 18-75 with primary sclerosing cholangitis (PSC) and cirrhosis for a research study. The purpose of the study is to determine the safest dose of cilofexor, an experimental medication, for use in patients with PSC and cirrhosis.

You may be eligible for this study if you have PSC and you have cirrhosis, but you do not have any complications from the cirrhosis.

Study involves taking an study drug by mouth once daily for 16 weeks, having 2 electrocardiograms (EKGs), answering questions about how you are feeling, blood work, and at home stool collection. There are at least 10 study visits, each visit will last 1-2 hours

Study-related exams, tests and study medication are all provided free of charge.